Answers are grounded in this paper and cite their sources.
The rapid rise of lead-halide perovskite solar cells has been tempered by lead toxicity, motivating a search for lead-free absorbers with comparable optoelec- tronics. Rubidium germanium iodide (RbGeI3) offers a direct, tunable bandgap, strong absorption, and improved environmental compatibility. Here we report a SCAPS-1D optimization of an RbGeI3 cell organized around its central liability, Ge2+ oxidation. After screening eight ETL–HTL combinations, the FTO/ TiO2/RbGeI3/CuI/Au architecture was carried forward on stability and cost grounds (a D2/NiO cross-check through the same pipeline reaches 28.16%, so this stack is not the efficiency optimum). Eleven parameters were varied se- quentially on one frozen deck; the consolidated device reaches 27.06% PCE. A Cu2O-like back-surface field raises the ideal point to 28.01% and recovers about one point on the identical full-realism stack (20.78% → 21.76%). Mapping VGe vacancy thermodynamics onto the defect ladder converts air exposure into a fab spec (Ef ≳ 0.46 eV holds the headline at 300 K equilibrium, 0.57–0.65 eV for anneal freeze-in; ambient falls below 20.76%), with a 15.53% current-state rung marking what first fabrication must beat. The solver pipeline is calibration- checked against experimental β-CsPbI3 [55], and SHAP analysis recovers bulk defects, bandgap and electron mobility as the dominant levers.
No takes yet. Share an insight, caveat, or question.
Fahim et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: